vs

Side-by-side financial comparison of ORRSTOWN FINANCIAL SERVICES INC (ORRF) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $64.6M, roughly 1.1× ORRSTOWN FINANCIAL SERVICES INC). ORRSTOWN FINANCIAL SERVICES INC runs the higher net margin — 33.8% vs -49.0%, a 82.8% gap on every dollar of revenue.

Orrstown Financial Services Inc is a US regional bank holding company headquartered in Shippensburg, Pennsylvania. It offers a full range of retail and commercial banking solutions including deposit accounts, personal and business loans, mortgages, and wealth management services, primarily serving customers across central Pennsylvania and northern Maryland.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

ORRF vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.1× larger
VRDN
$70.6M
$64.6M
ORRF
Higher net margin
ORRF
ORRF
82.8% more per $
ORRF
33.8%
-49.0%
VRDN

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ORRF
ORRF
VRDN
VRDN
Revenue
$64.6M
$70.6M
Net Profit
$21.8M
$-34.6M
Gross Margin
Operating Margin
-56.7%
Net Margin
33.8%
-49.0%
Revenue YoY
81958.1%
Net Profit YoY
19.1%
54.9%
EPS (diluted)
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORRF
ORRF
VRDN
VRDN
Q1 26
$64.6M
Q4 25
$64.9M
Q3 25
$64.4M
$70.6M
Q2 25
$62.4M
Q1 25
$60.4M
Q4 24
$61.8M
Q3 24
$64.1M
Q2 24
$33.3M
Net Profit
ORRF
ORRF
VRDN
VRDN
Q1 26
$21.8M
Q4 25
$21.5M
Q3 25
$21.9M
$-34.6M
Q2 25
$19.4M
Q1 25
$18.1M
Q4 24
$13.7M
Q3 24
$-7.9M
Q2 24
$7.7M
Operating Margin
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
42.3%
Q3 25
43.0%
-56.7%
Q2 25
39.6%
Q1 25
37.7%
Q4 24
27.7%
Q3 24
-15.4%
Q2 24
29.5%
Net Margin
ORRF
ORRF
VRDN
VRDN
Q1 26
33.8%
Q4 25
33.1%
Q3 25
34.0%
-49.0%
Q2 25
31.2%
Q1 25
29.9%
Q4 24
22.1%
Q3 24
-12.3%
Q2 24
23.3%
EPS (diluted)
ORRF
ORRF
VRDN
VRDN
Q1 26
$1.12
Q4 25
$1.11
Q3 25
$1.13
Q2 25
$1.01
Q1 25
$0.93
Q4 24
$0.35
Q3 24
$-0.41
Q2 24
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORRF
ORRF
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$161.8M
$490.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$603.2M
$503.0M
Total Assets
$5.6B
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORRF
ORRF
VRDN
VRDN
Q1 26
$161.8M
Q4 25
Q3 25
$490.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
ORRF
ORRF
VRDN
VRDN
Q1 26
$603.2M
Q4 25
$591.5M
Q3 25
$571.9M
$503.0M
Q2 25
$548.4M
Q1 25
$532.9M
Q4 24
$516.7M
Q3 24
$516.2M
Q2 24
$278.4M
Total Assets
ORRF
ORRF
VRDN
VRDN
Q1 26
$5.6B
Q4 25
$5.5B
Q3 25
$5.5B
$577.1M
Q2 25
$5.4B
Q1 25
$5.4B
Q4 24
$5.4B
Q3 24
$5.5B
Q2 24
$3.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORRF
ORRF
VRDN
VRDN
Operating Cash FlowLast quarter
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
$74.7M
Q3 25
$22.8M
$-84.6M
Q2 25
$24.5M
Q1 25
$11.0M
Q4 24
$35.0M
Q3 24
$7.5M
Q2 24
$6.4M
Free Cash Flow
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
$70.5M
Q3 25
$22.3M
$-84.7M
Q2 25
$23.7M
Q1 25
$8.6M
Q4 24
$33.4M
Q3 24
$7.1M
Q2 24
$6.4M
FCF Margin
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
108.6%
Q3 25
34.7%
-120.1%
Q2 25
37.9%
Q1 25
14.3%
Q4 24
54.0%
Q3 24
11.1%
Q2 24
19.2%
Capex Intensity
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
6.5%
Q3 25
0.8%
0.2%
Q2 25
1.3%
Q1 25
3.8%
Q4 24
2.6%
Q3 24
0.6%
Q2 24
0.1%
Cash Conversion
ORRF
ORRF
VRDN
VRDN
Q1 26
Q4 25
3.48×
Q3 25
1.04×
Q2 25
1.26×
Q1 25
0.61×
Q4 24
2.55×
Q3 24
Q2 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ORRF
ORRF

Net Interest Income$49.0M76%
Noninterest Income$15.6M24%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons